SciSparc's subsidiary can now send trial supplies to study sites, supporting site activation and patient enrollment. This advances testing, but the study has not yet shown whether the treatment works or is safe.
This lets SciSparc move from preparing supplies toward testing SCI-110 with patients. The study still must show whether the treatment works and is safe, so this step does not prove a medical benefit.
Follow SciSparc Ltd. (SPRC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SPRC